Chemours

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Chemical Solutions segment refers to the sale of chemicals used in industrial and consumer applications in the Americas. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemours overcomes Q4 challenges, eyes growth and sustainability in 2023

Chemours had a tough Q4 but a successful year overall, with a focus on margin improvement, growth in key businesses, and addressing legacy issues. The company is optimistic about 2023, emphasizing sustainability-led growth and returning value to shareholders.

Chemours reports strong Q1 performance, navigates challenges, eyes growth opportunities

Chemours' Q1 2023 Earnings Call highlighted strong performance, reaffirmed guidance, and emphasized margin improvement strategies. The company faces challenges from macroeconomic uncertainties and inflationary pressures but sees opportunities in sustainable initiatives and market-led innovation. Chemours remains confident in its full-year outlook and growth strategies.

Chemours reports record results, eyes cost reduction and innovation

Chemours had a strong quarter with record results and notable achievements in facility closures and settlements. While challenges lie ahead with a weaker second half expected, the company remains focused on shareholder value and strategic priorities. Opportunities in cost reduction, innovation, and market leadership position Chemours for future growth.

Chemours addresses challenges, eyes growth in sustainable solutions market

Chemours Company navigated challenges in Q3 2023, with a focus on long-term shareholder value and strategic transformation for performance improvement.
Strong performance in Performance Solutions and TSS business, alongside cost savings initiatives, position Chemours for future growth and margin recovery.
Management's commitment to driving value for shareholders amidst industry challenges underscores a proactive approach to addressing market dynamics.

Chemours reports Q4 sales growth, addresses TiO2 market challenges

Chemours is navigating challenges in the TiO2 market while focusing on cost reduction and growth opportunities in other segments. The company aims to maintain competitiveness through strategic decisions and investments in R&D. Analysts' inquiries during the earnings call highlighted concerns about leadership stability and various segment dynamics.

Chemours reports mixed Q1 results, eyes sequential growth in 2024

Chemours' Q1 2024 performance reflected mixed results across segments, with a focus on cost efficiencies, transformation plans, and maintaining liquidity amidst declining net sales and EBITDA.
Despite challenges in certain segments and market uncertainties, Chemours remains optimistic about sequential growth in the second quarter, aiming for significant EBITDA potential in 2024 and long-term financial improvement.
Strategic strengths in cost management, growth initiatives, and market opportunities position Chemours to navigate challenges, drive growth, and enhance profitability in a dynamic business environment.

Chemours exceeds volume expectations amidst challenges, anticipates sequential decline

Chemours demonstrated resilience and growth in key product lines despite facing challenges in Q1 and Q2.
The company's cost-saving efforts and recovery in certain segments highlight its ability to adapt to market conditions.
While financial results were impacted by one-time costs and a decline in net sales, Chemours maintained a strong net leverage ratio.
Anticipated sequential decline in net sales for Q3 underscores the need for strategic planning and operational optimization.

Chemours reports strong Q3 performance amidst strategic growth initiatives

Chemours' Q3 performance reflects operational strength and growth in key segments.
Challenges include declines in net sales for TSS and TT in Q4 and a net loss.
Opportunities exist in cost savings, growth in Opteon refrigerants, and strategic investments.
Overall, Chemours remains confident in its strategy to drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Other. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Other segment consists of performance chemicals and intermediates business. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

The Chemours Company Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – CC

NEW YORK , March 20, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Chemours Company (NYSE: CC) resulting from allegations that Chemours may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Chemours securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CC LOSS ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages The Chemours Company Investors to Inquire About Securities Class Action Investigation - CC

LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against The Chemours Company and Encourages Investors with Losses to Contact the Firm

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours and Partners Selected for $60M in U.S. Department of Energy Grants to Support Continued Advancement of Global Hydrogen Economy.

Chemours and Partners Selected for $60M in U.S. Department of Energy Grants to Support Continued Advancement of Global Hydrogen Economy

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Receives NYSE Notice Regarding Delayed Form 10-K Filing.

Chemours Receives NYSE Notice Regarding Delayed Form 10-K Filing

LOS ANGELES, CA / ACCESSWIRE / March 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against The Chemours Company and Encourages Investors with Losses to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of The Chemours Company (NYSE: CC) (“Chemours”). On February 13, 2024, during after-market hours, Chemours issued a press release announcing that the company had “postponed the release of its financial results and conference call related to the fourth quarter and full year ended December 31, 2023.

CC ALERT: Kessler Topaz Meltzer & Check, LLP is Investigating The Chemours Company (CC) for Possible Violations of Federal Securities Laws

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

The Chemours Company (CC) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

LOS ANGELES, CA / ACCESSWIRE / March 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against The Chemours Company and Encourages Investors with Losses to Contact the Firm

RADNOR, Pa. , March 11, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of The Chemours Company (NYSE: CC) ("Chemours").

Kessler Topaz Meltzer & Check, LLP Investigates The Chemours Company for Potential Securities Violations and Encourages Investors to Contact Firm

NEW YORK , March 11, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Chemours Company (NYSE: CC) resulting from allegations that Chemours may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Chemours securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages The Chemours Company Investors to Inquire About Securities Class Action Investigation - CC

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Chemours (CC) Stock?

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by The Chemours Company (CC)

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of federal securities laws. On February 13, 2024, after the market closed, Chemours disclosed that it was postponing the release of its financial results and conference call related to its fourth quarter and full year 2023. The Company further clarified, stating that it was del.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of The Chemours Company (CC) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

Shareholders That Lost Money on the Chemours Company (CC) Should Contact Levi & Korsinsky About Securities Fraud Investigation – CC

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Chemours investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your con.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of The Chemours Company (CC) on Behalf of Investors

LOS ANGELES , March 7, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Continues Investigation of The Chemours Company (CC) on Behalf of Investors

Chemours concluded an internal review it announced last week. The review found that three executives shifted the timing of payables and receivables to meet free cash flow targets and bolster their incentive compensation.

Why Chemours Stock Soared Today

An investigation has found that the Teflon maker's top executives shifted cash flows at year-end to hit targets that determined their annual stock and bonus awards.

Chemours Executives Improperly Shifted Deals to Boost Pay, Probe Finds

CC ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of The Chemours Company Shareholders Who Lost Money

LOS ANGELES, CA / ACCESSWIRE / March 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against The Chemours Company and Encourages Investors with Losses to Contact the Firm

WILMINGTON, Del.--(BUSINESS WIRE)--As previously disclosed, the Audit Committee of the Board of Directors of The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), with the assistance of independent outside counsel, has been overseeing an internal review. The review relates to an anonymous report made to the Chemours Ethics Hotline regarding the matters described below. A substantially complete report of the findings of the internal review was delivered to the full Board on March 5, 202.

Chemours Provides Update on Internal Review

NEW YORK--(BUSINESS WIRE)---- $CC #Investigation--The law firm of Kirby McInerney LLP continues its investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning whether Chemours and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On February 13, 2024, Chemours disclosed that it was postponing the release of its financial results and conference ca.

CC INVESTIGATION ALERT: Kirby McInerney LLP Continues Investigation on Behalf of The Chemours Company Investors

NEW YORK , March 5, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Chemours Company (NYSE: CC) resulting from allegations that Chemours may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Chemours securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CC INVESTOR ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages The Chemours Company Investors to Inquire About Securities Class Action Investigation - CC

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

News for Chemours Stock (CC)